logo-loader

Alnylam Pharmaceuticals

Receive alerts
Market:
NASDAQ
Market Cap:
$13.25 billion
Price
118.82 USD
Change
-0.44%
52 weeks high
125.65
52 weeks low
65.81

In brief

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection.